Prescription drug · ANDA
Prednisone NDC 51407-921
Prednisone 5 mg/1 · Tablet · Oral · Golden State Medical Supply, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51407-921-10 | 51407092110 | 1000 TABLET in 1 BOTTLE, PLASTIC (51407-921-10)Marketed from Jul 14, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Prednisone
- Generic name (nonproprietary)
- prednisone
- Active ingredients
- Prednisone — 5 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 080292
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 51407-921_2e6e74fa-2fa3-54bf-e063-6394a90abe04SPL ID 2e6e74fa-2fa3-54bf-e063-6394a90abe04SPL set ID 1e05e071-0407-0970-e063-6294a90a6c65RxCUI 198145, 312615, 312617UNII VB0R961HZT
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N451407092110followed by a unit qualifier and the quantityPackage 51407-0921-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Prednisone tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases m…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 080292
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Prednisone | Prednisone 5 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 0378-0640 |
| Prednisone | Prednisone 5 mg/1 | TabletOral | Northwind Health Company, LLC | 51655-765 |
| Prednisone | Prednisone 5 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2149 |
| Prednisone | Prednisone 5 mg/1 | TabletOral | QPharma, Inc. | 42708-136 |